Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy

Area of Science:

• Cardiology
• Molecular Biology
• Genetics

Background:

• Cardiac hypertrophy is a significant risk factor for heart failure and mortality, often triggered by injury and hemodynamic stress.
• Identifying molecular mechanisms that regulate cardiac hypertrophy is crucial for developing therapeutic strategies.

Purpose of the Study:

• To investigate the role of Kruppel-like factor 15 (KLF15) in regulating cardiac hypertrophy.
• To elucidate the molecular mechanisms by which KLF15 affects cardiac hypertrophy.

Main Methods:

• Assessed KLF15 expression in rodent models and human patient samples with cardiac hypertrophy.
• Utilized in vitro studies with neonatal rat ventricular cardiomyocytes to examine KLF15 function.
• Generated and analyzed KLF15-null mice under pressure-overload conditions.
• Performed promoter analyses and gel-shift assays to determine KLF15's molecular targets.

Main Results:

• KLF15 expression was found to be reduced in cardiac hypertrophy models and patient samples.
• Overexpression of KLF15 in cardiomyocytes inhibited hypertrophy, reducing cell size and hypertrophic gene expression.
• KLF15-null mice exhibited exacerbated cardiac hypertrophy, including ventricular dilatation and impaired systolic function, upon pressure overload.
• KLF15 was shown to inhibit the function of transcription factors GATA4 and myocyte enhancer factor 2.

Conclusions:

• KLF15 acts as a critical inhibitor of cardiac hypertrophy.
• KLF15 functions by suppressing key hypertrophic signaling pathways involving GATA4 and MEF2.
• These findings reveal a novel pathway regulating the cardiac response to hemodynamic stress, with KLF15 as a potential therapeutic target.